Fanatics Collectibles to Open Its First-Ever Global Flagship Store in the Spring of 2025, to Be Located on Iconic Regent Street in London
22.1.2025 13:00:00 CET | Business Wire | Press release
The Much-Anticipated Interactive Store Will Focus on Sports and Entertainment Trading Cards, Offer Exclusive Product and Host Events, Athletes and ClubsIncluded in Its Unique Footprint: An In-Store Breaking Area, a State-of-the-Art Trading-Card Singles Experience, Card Opening and Trading Areas and Customer Education Touchpoints
Today Fanatics Collectibles announced its first-ever flagship store, to open in the spring of 2025 on iconic Regent Street in London. The focus: sports and entertainment trading cards and trading-card games, featuring Fanatics Collectibles’ brands, including Topps, Merlin, Match Attax and Bowman. Last year Topps secured the exclusive trading-card rights to the Premier League, with product launching in time for the 2025/2026 season. Topps also currently has the exclusive rights for UEFA national team competitions and club competitions and will begin making licensed NBA product later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122281845/en/
(Photo: Fanatics Collectibles)
The much-anticipated store will span 803 square meters (8,647 square feet), and give collectors a one-of-a-kind experience seven days a week. The stunning visual centerpiece: a central display of the rarest and most-desirable cards, all with a giant suspended circular screen above. The flagship will offer exclusive product and have thousands of unique items, inclusive of single cards, retail boxes and high-end hobby releases. It will also see highly trafficked community-building events from monthly trade nights, kids rip events, athlete signings and appearances, partner activations and grading drop-off. Along with retail space, the store will feature a state-of-the-art breaking studio (live and taped opening of card packs), interactive customer education touchpoints – and a personal card creation suite.
“We are incredibly excited to cut the ribbon on this amazing community-building retail space, one that we hope will delight collectors and be a true home for the hobby in Europe,” said Topps President of Trading Cards, David Leiner. “It’ll be a destination for millions of fans as well as our own internal partners – and team and club partners, the latter using our dedicated space to launch and showcase new products in a way that has never been done before.” Speaking to internal partners, the new store will serve as a drop-off point for users of Fanatics Collect, a dynamic marketplace that connects buyers and sellers of trading cards. To the flagship being a home for fans and collectors, currently there are less than five Topps-partner hobby shops in the UK, and less than 30 in all of Europe. The annual footfall of south Regent Street is more than 70 million people.
While the store will focus primarily on trading cards, other items will be sold, including apparel (both Topps-branded and Fanatics-owned Mitchell & Ness) and memorabilia (signed kits, jerseys, balls and other equipment) and trading-card supplies. Types of trading-card products in the store: sports (soccer, football, baseball, F1, basketball, UFC, WWE), sports gaming cards (Match Attax) and entertainment (Disney, Marvel, Star Wars, Pixar, Garbage Pail Kids, Stranger Things).
About Fanatics Collectibles
Fanatics Collectibles is a new model and vision for the hobby fundamentally changing the experience for current and future collectors, leagues, and players across many professional and college sports. The organization secured long-term, exclusive rights to design, manufacture and distribute trading cards for several sports and entertainment properties, including MLB, MLBPA, the Premier League, MLS, UFC, Formula 1 as well as Disney, Marvel, Pixar and Star Wars, among others. In January 2022, Fanatics Collectibles announced the acquisition of Topps, establishing the preeminent licensed trading card brand as the cornerstone of Fanatics’ trading cards and collectibles business and jumpstarted its MLB and MLBPA rights to design, manufacture and distribute trading cards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122281845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom